Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9912512 | 0.95 | CYP1A2 (0.60) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| SCHEMBL9912526 | 0.92 | CYP1A2 (0.45) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| SCHEMBL15720867 | 0.91 | TP53 (0.45) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| Ena-001 SCHEMBL13835411 | 0.91 | CYP1A2 (0.44) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| Ena-001 SCHEMBL25246350 | 0.91 | CYP1A2 (0.44) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| SCHEMBL17169332 | 0.89 | HTT (0.46) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| SCHEMBL15720421 | 0.89 | CYP1A2 (0.43) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| SCHEMBL9107388 | 0.89 | CYP1A2 (0.41) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| SCHEMBL9912525 | 0.89 | KMT2A (0.50) | CYP1A2CYP2C19GAAL3MBTL1KMT2A | |
| SCHEMBL15739256 | 0.88 | CYP1A2 (0.42) | CYP1A2CYP2C19GAAL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | ENALARE THERAPEUTICS INC. (US) | 2026-02-10 | — | — | US | claimed |
| EP-4543455-A2 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | Enalare Therapeutics Inc. (US) | 2025-04-30 | — | — | EP | claimed |
| WO-2025080559-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | claimed |
| EP-4504206-A2 | RESPIRATORY STIMULANT NASAL FORMULATIONS | Enalare Therapeutics Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| US-12011428-B2 | Compositions and methods for stimulating ventilatory and/or respiratory drive | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-06-18 | — | — | US | claimed |
| US-20230414624-A1 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | ENALARE THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | claimed |
| WO-2023250141-A2 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | ENALARE THERAPEUTICS INC. (US) | 2023-12-28 | — | — | WO | claimed |
| US-20230338319-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-26 | — | — | US | claimed |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-10-05 | — | — | US | claimed |
| WO-2023192602-A2 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. (US) | 2023-10-05 | — | — | WO | claimed |
| US-20230042176-A1 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | NAT UNIV SINGAPORE (SG) | 2023-02-09 | — | — | US | claimed |
| EP-4076471-A1 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | National University of Singapore (SG) | 2022-10-26 | — | — | EP | claimed |
| US-20220241268-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC. | 2022-08-04 | — | — | US | claimed |
| CN-114173872-A | Methods and pharmaceutical compositions for treating drug overdose | 依那拉治疗股份有限公司 | 2022-03-11 | — | — | CN | claimed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | claimed |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | claimed |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | claimed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | claimed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | claimed |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4739375-A1 | HIGHLY PORTABLE GAS DELIVERY SYSTEMS | Minogue, Michael R. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | ENALARE THERAPEUTICS INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250325554-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | ENALARE THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12337000-B2 | Therapeutic modulators of the reverse mode of ATP synthase | FORREST MICHAEL DAVID (GB) | 2025-06-24 | — | — | US | disclosed |
| WO-2025106940-A1 | HIGHLY PORTABLE GAS DELIVERY SYSTEMS | MINOGUE MICHAEL R (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250152889-A1 | HIGHLY PORTABLE GAS DELIVERY SYSTEMS | MINOGUE, MICHAEL | 2025-05-15 | — | — | US | disclosed |
| EP-4543455-A2 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | Enalare Therapeutics Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025082731-A1 | INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA | MOSANNA THERAPEUTICS AG (CH) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025080559-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2025-04-10 | — | — | US | disclosed |
| US-20250057851-A1 | Therapeutic Modulators of the Reverse Mode of ATP Synthase | FORREST MICHAEL DAVID (GB) | 2025-02-20 | — | — | US | disclosed |
| EP-4504206-A2 | RESPIRATORY STIMULANT NASAL FORMULATIONS | Enalare Therapeutics Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20250032496-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-12138267-B2 | Methods of treating respiratory depression modulated by a non-opioid agent | ENALARE THERAPEUTICS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-4456900-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | Enalare Therapeutics Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240335410-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | UNIV CASE WESTERN RESERVE (US) | 2024-10-10 | — | — | US | disclosed |
| US-12090276-B1 | Highly portable gas delivery systems | Minogue, Michael R. (US) | 2024-09-17 | — | — | US | disclosed |
| CN-118652215-A | Therapeutic modulators of ATP synthase reverse pattern | 迈克尔·大卫·福雷斯特 | 2024-09-17 | — | — | CN | disclosed |
| EP-4426308-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | Enalare Therapeutics Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | ENALARE THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-12011428-B2 | Compositions and methods for stimulating ventilatory and/or respiratory drive | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-06-18 | — | — | US | disclosed |
| EP-4333852-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Enalare Therapeutics Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023250141-A2 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | ENALARE THERAPEUTICS INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230414624-A1 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | ENALARE THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2023225177-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | ENALARE THERAPEUTICS INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230338319-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | CASE WESTERN RESERVE UNIVERSITY | 2023-10-26 | — | — | US | disclosed |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023192602-A2 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-10-05 | — | — | US | disclosed |
| EP-3316890-B1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME | NEURAD LTD (IL) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023129502-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ENALARE THERAPEUTICS INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230210857-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210857-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210857-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ENALARE THERAPEUTICS INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023081185-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230142073-A1 | Almitrine for treating the hypoxemia of a coronavirus infection | FORREST MICHAEL DAVID (GB) | 2023-05-11 | — | — | US | disclosed |
| US-20230140606-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230140606-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230140606-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | ENALARE THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230042176-A1 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | NAT UNIV SINGAPORE (SG) | 2023-02-09 | — | — | US | disclosed |
| US-20230042176-A1 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | NAT UNIV SINGAPORE (SG) | 2023-02-09 | — | — | US | disclosed |
| US-20230042176-A1 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | NAT UNIV SINGAPORE (SG) | 2023-02-09 | — | — | US | disclosed |
| WO-2022235771-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | ENALARE THERAPEUTICS INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4076471-A1 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | National University of Singapore (SG) | 2022-10-26 | — | — | EP | disclosed |
| EP-4076471-A1 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | National University of Singapore (SG) | 2022-10-26 | — | — | EP | disclosed |
| US-20220241268-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC. | 2022-08-04 | — | — | US | disclosed |
| EP-3324975-B1 | COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF | HSU JOHN (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114173872-A | Methods and pharmaceutical compositions for treating drug overdose | 依那拉治疗股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | NEURAD LTD. (IL) | 2019-05-21 | — | — | US | disclosed |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | NEURAD LTD. (IL) | 2018-05-24 | — | — | US | disclosed |
| US-20180021303-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | CANBEX THERAPEUTICS LTD (GB) | 2018-01-25 | — | — | US | disclosed |
| US-20180021303-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | CANBEX THERAPEUTICS LTD (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9643971-B2 | Breathing control modulating compounds, and methods of using same | GALLEON PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS INC (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS INC (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS INC (US) | 2016-09-08 | — | — | US | disclosed |
| WO-2016128772-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351972-B2 | Compounds as respiratory stimulants for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160046635-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2016-02-18 | — | — | US | disclosed |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9162992-B2 | Compounds and compositions for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9162992-B2 | Compounds and compositions for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9162992-B2 | Compounds and compositions for treatment of breathing control disorders or diseases | GALLEON PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | GALLEON PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. | 2014-12-18 | — | — | US | disclosed |
| WO-2013181217-A2 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | GALLEON PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | WO | disclosed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | GALLEON PHARMACEUTICALS, INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (29 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | OPRK1, OPRD1, OPRM1 | CYP1A2 138/4885CYP2C19 308/4885GAA 1777/4885 |
| US-20120142647-A1 | Novel Compounds as Respiratory Stimulants for Treatment of Breathing Control Disorders or Diseases | MTNR1B, CHRM3, ADRA2C | CYP1A2 457/4885CYP2C19 672/4885GAA 342/4885 |
| US-12138267-B2 | Methods of treating respiratory depression modulated by a non-opioid agent | OPRK1, OPRM1, OPRD1 | CYP1A2 923/4885CYP2C19 1046/4885GAA 1826/4885 |
| US-20230042176-A1 | METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | UBE3A, UBE3C, UBQLN1 | CYP1A2 3398/4885CYP2C19 4821/4885GAA 1690/4885 |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ADRA2B, ADRB1, ADRB2 | CYP1A2 89/4885CYP2C19 93/4885GAA 1929/4885 |
| US-20120295911-A1 | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases | PER2, SMPD4, NDUFB5 | CYP1A2 1058/4885CYP2C19 1600/4885GAA 563/4885 |
| US-20180021303-A1 | BKCA CHANNEL ACTIVATOR FOR TREATING MUSCULAR DISORDER | KCNMA1, KCNMB1, KCNA1 | CYP1A2 4827/4885CYP2C19 4841/4885GAA 727/4885 |
| US-20250325554-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | NDUFB6, NDUFB7, CHRM5 | CYP1A2 895/4885CYP2C19 801/4885GAA 804/4885 |
| US-12337000-B2 | Therapeutic modulators of the reverse mode of ATP synthase | ATP5ME, ATP5F1A, ATP5MG | CYP1A2 1341/4885CYP2C19 1784/4885GAA 382/4885 |
| US-20250032496-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | OPRK1, OPRM1, OPRD1 | CYP1A2 923/4885CYP2C19 1046/4885GAA 1826/4885 |
| US-20150291597-A1 | NOVEL ORALLY BIOAVAILABLE BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | MTNR1B, TNNC1, PER2 | CYP1A2 531/4885CYP2C19 648/4885GAA 723/4885 |
| US-20180141953-A1 | Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same | MTNR1B, CHRM3, PER2 | CYP1A2 2209/4885CYP2C19 2870/4885GAA 1936/4885 |
| US-20140371224-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | PER2, MTNR1B, NDUFB5 | CYP1A2 2352/4885CYP2C19 3493/4885GAA 530/4885 |
| US-20230310440-A1 | RESPIRATORY STIMULANT NASAL FORMULATIONS | ADRA2C, MTNR1B, MTNR1A | CYP1A2 175/4885CYP2C19 154/4885GAA 1200/4885 |
| US-20160256463-A1 | NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | P2RX5, HRH2, ADRA2C | CYP1A2 472/4885CYP2C19 677/4885GAA 672/4885 |
| US-20230140606-A1 | METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT | OPRK1, OPRM1, OPRD1 | CYP1A2 923/4885CYP2C19 1046/4885GAA 1826/4885 |
| US-20240335410-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | GSTM1, GSTO1, GSR | CYP1A2 1422/4885CYP2C19 1450/4885GAA 3391/4885 |
| US-20220241268-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | OPRK1, OPRM1, ADRB1 | CYP1A2 135/4885CYP2C19 213/4885GAA 667/4885 |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ADRA2A, ADRA2C, OPRM1 | CYP1A2 50/4885CYP2C19 288/4885GAA 434/4885 |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | KCNN2, KCNN1, KCNN3 | CYP1A2 2714/4885CYP2C19 2565/4885GAA 670/4885 |
| US-20250057851-A1 | Therapeutic Modulators of the Reverse Mode of ATP Synthase | ATP5ME, ATP5F1A, ATP5MG | CYP1A2 2094/4885CYP2C19 2851/4885GAA 478/4885 |
| US-20150374706-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES | PER2, SMPD4, NDUFB5 | CYP1A2 1058/4885CYP2C19 1600/4885GAA 563/4885 |
| US-20230142073-A1 | Almitrine for treating the hypoxemia of a coronavirus infection | ACE2, HIF1A, ACE | CYP1A2 2045/4885CYP2C19 1258/4885GAA 1398/4885 |
| US-20230210857-A1 | RESPIRATORY STIMULANT PARENTERAL FORMULATIONS | ADRA2C, ADRA1B, CHRM3 | CYP1A2 82/4885CYP2C19 30/4885GAA 1061/4885 |
| US-10294228-B2 | Breathing control modulating compounds, and methods of making and using same | MTNR1B, PDE3A, CHRM3 | CYP1A2 1724/4885CYP2C19 2435/4885GAA 1576/4885 |
| US-12011428-B2 | Compositions and methods for stimulating ventilatory and/or respiratory drive | GSTM1, GSTO1, GSR | CYP1A2 1422/4885CYP2C19 1450/4885GAA 3391/4885 |
| US-20160046635-A1 | NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF USING SAME | PRDX5, QDPR, P2RX5 | CYP1A2 1766/4885CYP2C19 1573/4885GAA 1650/4885 |
| US-20230414624-A1 | METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY | SDHA, NDUFB7, OTC | CYP1A2 1437/4885CYP2C19 1703/4885GAA 258/4885 |
| US-20230338319-A1 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE | GSTM1, GSTO1, GSR | CYP1A2 1422/4885CYP2C19 1450/4885GAA 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.